RxDoctor Payments Data

Tarif Kanaan, MD

Cardiovascular Disease · Toledo, OHNPI 1407858061

Payments from drug & device makers

$3,723in general payments, 2019–2025

Across 69 payments — averaging $53.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Abiomed$457
  • AstraZeneca$326
  • Johnson & Johnson$252
  • Esperion Therapeutics, Inc.$213
  • Amgen$208
  • plus $922 from 13 others

What the payments were for

  • Food & beverage$3,706100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,723 in reported general payments places this provider in the 60th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$217,003
Medicare patients
1,114
Services billed
2,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban408$437,613
XareltoRivaroxaban109$112,931
EntrestoSacubitril/Valsartan78$93,153
BrilintaTicagrelor71$61,082
Repatha SureclickEvolocumab74$52,113
FarxigaDapagliflozin Propanediol22$31,026
JardianceEmpagliflozin16$18,445
Amiodarone Hcl189$7,671
ClopidogrelClopidogrel Bisulfate510$7,326
Dabigatran EtexilateDabigatran Etexilate Mesylate17$7,110
Atorvastatin Calcium550$5,829
Metoprolol Succinate389$5,507
Ranolazine ErRanolazine101$5,190
Metoprolol Tartrate568$3,880
Flecainide Acetate83$3,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$133$437,613408 claims
Johnson & JohnsonXarelto$252$112,931109 claims
NovartisEntresto$56$93,15378 claims
AstraZenecaBrilinta, Farxiga$326$92,10893 claims
Boehringer IngelheimJardiance$150$18,44516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →